JSS Medical Research establishes its presence in Europe

Monday, June 6, 2016 Research News J E 4

— JSS Medical Research, an international contract research organization active in over 20 countries acquires Bonne Santé in Poland as catalyst for European expansion

MONTREAL, June 6, 2016 /PRNewswire/ - JSS Medical Research Inc., an International Contract Research Organization (CRO) with offices in Canada, Latin America and Asia/ Pacific, announced the acquisition of Bonne Santé, a Polish CRO, to accelerate the expansion into Europe.


JSS Medical Research provides the entire range of clinical research services to the global pharmaceutical, biotechnology and medical device industries. The worldwide expansion is driven by the growing demands of its clients for presence in these countries. Presently the largest Canadian-owned CRO, JSS Medical Research has offices in Canada, Colombia, India and Poland with more than 300 full time employees.

Dr. John S Sampalis, President and CEO of JSS Medical Research said: 'The decision to acquire Bonne Santé was based on the excellent reputation of the Company built over 25 years, the highly regarded management and staff, established long-term hospital and investigator relations and customer-focused philosophy. While the spectrum of phase II – IV offerings of the two companies are comparable, Bonne Santé will now provide the foundation upon which we can leverage our expertise in late phase, post marketing, epidemiological and health economics / outcomes research to provide our clients with an enhanced spectrum of clinical research covering all pre- and post-marketing phases.

The acquisition will focus on the competitive advantages realized by the complementary geographical coverage of the two companies, operational efficiencies and international business development to expand client / patient service offerings. This expansion enables us to provide our services to our large pharmaceutical clients and their regional affiliates in Europe and surrounding regions. For our biotech clients the expansion will provide them with access to academics, key opinion leaders, investigators and that will facilitate the completion of their clinical development programs and access to the European markets.

Stella Boukas, COO at JSS Medical Research added: "The operational efficiencies realized through our merger and acquisition strategy will translate to expedited project completion without compromising quality."

About JSS Medical Research

JSS Medical Research is a full?service International Contract Research Organization (CRO) with its corporate office in Montreal, Canada and regional offices in Colombia and India. The company offers comprehensive clinical trial management services from study design to publication of results, in Phase I?IV trials across a broad range of therapeutic areas. With science and clinical epidemiological expertise at its core and early phase services of the highest quality adhering to industry standards, JSS Medical Research is a leader in Post?Approval Clinical Epidemiology Studies (PACES) including Post?Marketing Observational Studies, Health Outcomes Research (HEOR) and Health Economics. Currently, JSS Medical Research is conducting research studies in over 21 countries around the world for its clients that include the top 25 Pharmaceutical companies and Biotechnology/Device companies, worldwide.

For more information, visit

About Bonne Santé

Bonne Santé was established in Poland in 1990 by Albert Czetwertynski as a marketing company specializing in promotion of pharmaceutical products. Responding to a growing  demand, in 1999 Bonne Santé began conducting clinical trials in Poland for its clients. The company's reputation for excellent quality, often exceeding client expectations, efficiency that was combined with competitive cost and flexibility to address the needs of the project made Bonne Santé one of the most successful CROs in the region. Currently the Company provides clinical research, regulatory and consulting services covering Phase II – IV studies for a wide range of regional and international companies.

For more information, visit


SOURCE JSS Medical Research Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Frontier Biotech's Long-acting HIV-1 Fusion Inhibi...
Ganymed's IMAB362 Extends Survival in Gastric Canc...